IL17A and systemic sclerosis: No definitive evidence can prove the role of IL-17A in lung fibrosis progression involved in SSc patients (1).The dichotomous nature of IL-17 lies in that it is pro-fibrotic in animal models while having a dual pro-inflammatory and anti-fibrotic role in humans (36).